The Body PRO Covers: The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy

Viruses, Fungi and Bacterial Pathogenesis (Late-Breaker Slide Session 164b)

December 18, 2001

  • Safety and Efficacy of Tipranavir (TPV), a Novel Non-Peptidic Protease Inhibitor, Plus Ritonavir (RTV) in PI-Failure Patients
    Abstract LB-15
    Authored by L. Slater (Univ. of Oklahoma Health Sciences Center, Oklahoma City, OK), C. Farthing (AIDS Healthcare Foundation, Los Angeles, CA), J. Jayaweera (Jackson Medical Center, Miami, FL), M. Para (Ohio State Univ. Medical Center, Columbus, OH), D. Haas (Vanderbilt Univ., Nashville, TN), C. Dohnanyi (Boehringer Ingelheim Pharma, Ridgefield, CT), V. Kohlbrenner (Boehringer Ingelheim Pharma, Ridgefield, CT), S. Mccallister (Boehringer Ingelheim Pharma, Ridgefield, CT), D. Mayers (Boehringer Ingelheim Pharma, Ridgefield, CT)
    View the original abstract

Tipranavir is a potentially important new protease inhibitor. It has a different structure from the currently used protease inhibitors in that it is not a mimic of a small protein (non peptidic) and it is a very flexible molecule. In the lab, it remains active against 95 percent of viruses that are resistant to multiple drugs.

Tipranavir's development has been slow. The first clinical trial was presented in Geneva in 1998, but further clinical development did not proceed until after Boehringer Ingelheim acquired the drug. A new formulation reduced the pill burden, and it became clear that dosing with ritonavir was needed to keep levels high enough for a 12 hour period.

Today's presentation during the late-breaker session gave 16-week data from study 1182.4. This study was aimed at patients in "first failure," defined as failing one protease inhibitor and having at least two new nucleosides available. Sixty-three patients were randomized to one of three arms. One arm received 500mg of tipranavir (two capsules) with 100mg of ritonavir. The second received 1,250mg (five capsules) of tipranavir with 100mg of ritonavir, and the control arm received 400mg of ritonavir with 400mg of saquinavir. All patients started two new nucleosides.

The median viral load at baseline was about 30,000 copies, suggesting that the patients had been failing for several months. Viral load dropped rapidly in all three arms, with the greatest change (more than a two-log drop) occurring in the high-dose tipranavir arm. By several measures, the viral load response was greater in the high dose arm than the low-dose arm, and both were slightly more active than the ritonavir/saquinavir arm. The proportion reaching the more traditional endpoints of less than 400 copies or less than 50 copies was not reported.

More patients withdrew in the ritonavir/saquinavir arm either for side effects or other reasons. Side effects in a small trial can be misleading, but the low-dose ritonavir arm was better tolerated than either ritonavir/saquinavir or high dose tipranavir. Nausea, vomiting and diarrhea were the primary side effects, seen in 5 to 14% of the low-dose arm and 19 to 33% in the high-dose arm.

Tipranavir remains a very interesting and important compound. However, this presentation did not answer many of the important questions. Limited virology was presented. Thus, we do not know how well the drug works in patients with more difficult viruses. Many patients failing their first regimen do not have protease inhibitor-resistant virus, and tipranavir may be more useful to patients with multiple treatment failures. Durability of response is important in salvage, so 16-week data is of limited importance. Lastly, we really only understand tolerability when larger studies look at the final doses. However, key upcoming studies will address all of these points, and hopefully will show that we have a new option for patients who have exhausted their protease inhibitor options.

Previous Session | Next

Tell us what you think of The Body's conference coverage!

This article was provided by TheBodyPRO. It is a part of the publication 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001).

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.